OLMA Olema Pharmaceuticals, Inc.

NASDAQ
$7.06

Olema Pharmaceuticals, Inc. (OLMA) is expected to report earnings on February 9, 2027, after the market close. The consensus earnings estimate is a loss of $0.70 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -3.0% since its last earnings release on November 10, 2026.

Olema Pharmaceuticals Missed Consensus Estimates
Tuesday, November 10, 2026 · 7:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 9
Tuesday · 4:00 PM ET
Earnings Whisper
-
vs ($0.70)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $7.48

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in discovery, development and commercialization of therapies for women's cancers. The company's product pipeline includes OP-1250, which is in clinical stage. Olema Pharmaceuticals Inc. is based in San Francisco, California.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.